Huapont Invests $3 Million in Angionetics for Novel CV Treatment

Huapont Life Sciences of Chongqing will make a $3 million investment into San Diego's Angionetics. In return, Huapont will gain China rights to Angionetics' Generx® (Ad5FGF-4), which is designed to increase microvasculature as a treatment for ischemic heart disease and refractory angina. Angionetics will use the investment for a US Phase III trial of Generx, while Huapont will be responsible for its China registration. After the investment, Huapont will own 15% of Angionetics. Angionetics is a subsidiary of Taxus Cardium Pharmaceuticals. More details.... Stock Symbol: (SHZ: 002004) (NSDQ: CRXM) Share this with colleagues: // //